

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-24. (cancelled)

25. (currently amended) A controlled release tablet or mini-tablet ~~composition~~ composition, consisting essentially of:

a hydrophilic first matrix comprising a lipophilic phase and an amphiphilic phase,

wherein said lipophilic phase and said amphiphilic phase are in a second matrix together, and said second matrix is dispersed throughout the hydrophilic first matrix,

wherein said hydrophilic first matrix consists of compounds selected from the group consisting of acrylic or methacrylic acid polymers, acrylic copolymers, methacrylic copolymers, alkyl vinyl polymers, hydroxyalkylcellulose, carboxyalkylcellulose, polysaccharides, dextrans, pectines, starches, starch derivatives, alginic acid, natural gums, synthetic gums, and poylyalcohols,

wherein said lipophilic phase is in a granular form and consists of compounds with a melting point between 40 and 90°C and an active ingredient at least partially incorporated in said lipophilic phase,

wherein said amphiphilic phase comprises an active ingredient at least partially incorporated in said amphiphilic phase.

26. (canceled)

27. (previously presented) The composition according to claim 25, further comprising compounds that are polar lipids of type I or II, ceramides, glycol alkyl ethers, esters of fatty acids with polyethylene glycols or diethylene glycols.

28. (previously presented) The composition according to claim 25, wherein the lipophilic phase comprises one or more compounds selected from the group consisting of unsaturated or hydrogenated alcohols or fatty acids, salts, esters or amides thereof, mono-, di- or triglycerides of fatty acids, the polyethoxylated derivatives thereof, waxes, and cholesterol derivatives.

29. (previously presented) The composition according to claim 25, wherein the hydrophilic matrix consists of hydrogel-forming compounds.

30. (canceled).

31. (previously presented) The composition according to claim 25, further comprising a gastro-resistant coating.

32. (previously presented) The composition according to claim 31, wherein the gastro-resistant coating consists of methacrylic acid polymers or cellulose derivatives.

33. (currently amended) The composition according to claim 25, wherein said composition is in the form of tablets, ~~capsules or minitables.~~

34. (currently amended) The composition according to claim 26, wherein said composition is in the form of ~~tablets,~~ ~~capsules or minitables.~~

35. (previously presented) The composition according to claim 25, in which the active ingredient belongs to the therapeutical classes of analgesics, antitussives, bronchodilators, antipsychotics, selective β 2 antagonists, calcium antagonists, antiparkinson drugs, non-steroidal anti-inflammatory drugs, antihistamines, antidiarrheals and intestinal

antiinflammatories, spasmolytics, anxiolytics, oral anti-diabetics, cathartics, antiepileptics, topical antimicrobials.

36. (previously presented) The composition according to claim 25, wherein the active ingredient is selected from the group consisting of mesalazine (5-aminosalicylic acid), budesonide, metformin, octylonium bromide, gabapentin, carbidopa, nimesulide, propionylcarnitine, isosorbide mono- and dinitrate, naproxen, ibuprofen, ketoprofen, diclofenac, thiaprophenic acid, nimesulide, chlorhexidine, benzydamine, tibezone iodide, cetylpyridinium chloride, benzalkonium chloride, and sodium fluoride.

37. (previously presented) The composition according to claim 25, further comprising bioadhesive substances.

38. (previously presented) A pharmaceutical composition, comprising the composition according to claim 25, in the form of tablets chewable or erodible in the buccal cavity or in the first portion of the gastrointestinal tract.

39. (previously presented) The method according to claim 25, wherein the amphiphilic matrix comprises 5 to 95% by weight of an active ingredient.